Neurocrine Biosciences Inc.
- BID
154
- ASK
155.25
- 478 Units474 Units
- 07/24, 20:00:10 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
35.71%
Market Cap
-
P/E Ratio
30.38
Dividend Yield
0.00 %
Earnings per Share
4.14 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 154.45 G | 0 Units |
| PRICE DETERMINATION TIME | 07/24/2026 / 07:31:55 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 155.1 | 151.05 |
| PREV. DAY'S PRICE | 152.95 | (07/23) |
| CHANGE DAY BEFORE | +1.50 | 0.98 % |
| 52 WEEK HIGH / LOW | 159.8 (07/10) | 102.45 (02/13) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 2.29 | 3.04 | 4.14 | 6.97 | 9.09 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | 53.29 | 41.47 | 30.38 | 21.96 | 16.84 |
PRICE - BOOK RATIO | 5.83 | 5.24 | 4.36 | - | - |
PRICE - SALES RATIO | 7.05 | 6.01 | 5.08 | - | - |
PRICE - CASH FLOW RATIO | 34.13 | 23.77 | 18.57 | - | - |
Master Data
| WKN | 900964 |
| ISIN | US64125C1099 |
| SYMBOL | NB3 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | NEUROCRINE BIOSCI. |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 2.03 % | 7.86 % | 38.17 % | 33.00 % | 35.71 % | 73.14 % | 84.37 % | 26.40 % |
| HIGH | 158.10 | 159.80 | 159.80 | 159.80 | 159.80 | 159.80 | 159.80 | 159.80 |
| LOW | 147.35 | 140.50 | 107.55 | 102.45 | 102.45 | 77.30 | 63.62 | 102.45 |
Dividende
pro Aktie
NEUROCRINE BIOSCI. does not deliver dividend information
Company profile
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Structured products for Neurocrine Biosciences Inc.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.